Found 161 articles for: "ustekinumab"
Secukinumab: Long-term Safety and Efficacy in Psoriasis
August 2017 | Volume 16 | Issue 8 | Supplement Individual Articles | 115 | Copyright © August 2017
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study
August 2017 | Volume 16 | Issue 8 | Original Article | 801 | Copyright © August 2017
INTRODUCTION: Many options are available for patients with moderate to severe plaque psoriasis. Patients with moderate disease, however, are often undertreated and do not achieve satisfactory clear...
Read MoreAdalimumab in Chronic Plaque Psoriasis: A Clinical Guide
August 2017 | Volume 16 | Issue 8 | Original Article | 779 | Copyright © August 2017
Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treat...
Read MoreTreatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation
August 2017 | Volume 16 | Issue 8 | Original Article | 760 | Copyright © August 2017
Inverse or intertriginous psoriasis commonly involves skin fold areas including the axillae, perianal skin, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds. ...
Read MoreMethods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results
August 2017 | Volume 16 | Issue 8 | Original Article | 734 | Copyright © August 2017
BACKGROUND: An issue in long-term clinical trials of biologics in psoriasis is how to handle missing efficacy data. This methodological challenge may not be understood by clinicians, yet can have a...
Read MoreA Major Win for the Treatment of Nail Psoriasis
August 2017 | Volume 16 | Issue 8 | Editorials | 731 | Copyright © August 2017
Despite mounting evidence that biologics provide the fastest and most efficacious for nail psoriasis, it remains challenging for patients to get access to these medications, often requiring concomitan...
Read MoreInjection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis
July 2017 | Volume 16 | Issue 7 | Case Reports | 695 | Copyright © July 2017
Psoriasis is a chronic inflammatory cutaneous disease that affects 2-3% of the general population. Up to 30% of patients with psoriasis also develop psoriatic arthritis, a chronic inflammatory and ...
Read MoreDrivers of Healthcare Costs Among the Costliest Patients With Psoriasis Over Three Years in a United States Health Plan
July 2017 | Volume 16 | Issue 7 | Original Article | 651 | Copyright © July 2017
OBJECTIVE: To compare patients with psoriasis by cost level over 3 years.
METHODS: Psoriasis patients in a large US health plan in 2011-2013 were identified. Four groups were created by h...
Read MoreDermatologists: Collaborating With Payers to Optimize Coverage Policies
March 2017 | Volume 16 | Issue 3 | Original Article | 228 | Copyright © March 2017
Dermatologists are frustrated by payer constraints that limit their ability to optimize patient treatment. They can benefit from understanding the payer formulary process and places in that process wh...
Read MorePatient Preference for Dosing Frequency Based on Prior Biologic Experience
March 2017 | Volume 16 | Issue 3 | Original Article | 220 | Copyright © March 2017
Background: There is limited research exploring patient preferences regarding dosing frequency of biologic treatment of psoriasis. Methods: Patients with moderate-to-severe plaque psoriasis identifie...
Read MoreUse of Biologics in Private Practice: Nine Years of Lessons and Learning
March 2017 | Volume 16 | Issue 3 | Original Article | 215 | Copyright © March 2017
Over a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects p...
Read MoreReversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab
February 2017 | Volume 16 | Issue 2 | Case Reports | 177 | Copyright © February 2017
The use of monoclonal antibodies against interleukin (IL)-12 and -23, such as ustekinumab, has considerably reduced the disease burden in many patients with moderate to severe psoriasis. Reversible po...
Read MoreEfficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris: a Randomized Phase III Study (PSO-FAST)
December 2015 | Volume 14 | Issue 12 | Original Article | 1468 | Copyright © December 2015
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) designed to improve treatment outcomes.
OBJECTIVE: To compare the ef...
Read MoreAnti-IL-23 Phase II Data for Psoriasis: A Review
October 2015 | Volume 14 | Issue 10 | Original Article | 1093 | Copyright © October 2015
BACKGROUND: Monoclonal antibodies that target both Interleukin (IL)-12 and IL-23 have shown great efficacy in the treatment of psoriasis. Recent evidence suggests that IL-23 serves a more critical rol...
Read MoreTime to Raise the Bar to Psoriasis Area Severity Index 90 and 100
October 2015 | Volume 14 | Issue 10 | Editorials | 1086 | Copyright © October 2015
Tumor Necrosis Factor-α Inhibitor Use in Psoriasis Patients With a First-degree Relative With Multiple Sclerosis
August 2015 | Volume 14 | Issue 8 | Original Article | 876 | Copyright © August 2015
Tumor necrosis factor (TNF)-α inhibitors are currently the gold standard for treating moderate to severe plaque psoriasis and other immune-mediated diseases. The presence of previously existing ...
Read MoreBiologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis
August 2015 | Volume 14 | Issue 8 | Original Article | 846 | Copyright © August 2015
BACKGROUND/OBJECTIVE: Despite the aging population, few studies have documented the treatment of geriatric psoriasis. The purpose of this study is to compare the efficacy, safety, and prescribing patt...
Read MoreEssential Truths for the Care and Management of Moderate-to-Severe Psoriasis
August 2015 | Volume 14 | Issue 8 | Original Article | 805 | Copyright © August 2015
Psoriasis is a systemic inflammatory disease. Effective management requires treatment with agents targeting inflammation in skin, joints, and other tissues. Biologics for psoriasis are directed at mor...
Read MoreEmerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib
August 2015 | Volume 14 | Issue 8 | Original Article | 786 | Copyright © August 2015
BACKGROUND: Increased knowledge of the molecular regulatory mechanisms that contribute to the pathogenesis of psoriasis and other inflammatory diseases has created new opportunities for the developmen...
Read MoreSafety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
July 2015 | Volume 14 | Issue 7 | Original Article | 706 | Copyright © July 2015
BACKGROUND: Safety surveillance is needed for biologic therapies for psoriasis.
OBJECTIVE: To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab and other psoriasis t...
Read More